Introduction
A risk-benefit analysis is simply a comparison of the risks of treatment against the benefits. It assumes great importance when the benefits are not dramatic, nor universal and do not obviously outweigh any risk. The treatment of malignant hypertension is an example when the risks are relatively unimportant. In 1961, Pickering, Cranston and Peers provided an overview of the results of treating malignant hypertension.' Untreated, 50% die within 6 months and 90% within a year. Treatment ensured that, in 1960, at least 50% survived 2 years. Nevertheless, risks cannot be ignored, and in this condition enthusiasm for immediate pressure reduction with intravenous drugs has given way to a gradual reduction, thus avoiding the rare but real precipitation of stroke events observed with precipitious falls in pressure. This review is concerned with prevention of the cardiovascular complications of hypertension rather than the treatment of acute life-threatening conditions and these benefits must be considered in the light of the following. This is only a superficially easy question to answer as the rates vary with age, gender, severity of hypertension, geographic area, race, and the presence and degree of other risk factors. To take an example: if we argue for the treatment of hypertension on the main grounds of reducing coronary heart disease, this may not influence a Japanese doctor whose patients are less likely to experience this problem.
(b) How often is the complication actually due to hypertension?
Cerebral haemorrhage is much more likely than coronary heart disease to be the result of hypertension. However, although the strength of the association (given by the relative risk of something happening if you are hypertensive compared to not hypertensive) may be greater for cerebral haemorrhage, the importance of treatment may be greater for coronary heart disease in the Western world as this is much more common than cerebral haemorrhage. The potential importance of treatment is given by the attributable risk which is the incidence of disease in hypertensives (expressed as a rate/ year) less the incidence in non-hypertensives. The problem is that the potential gains from treatment may not match the gains observed in the experimental situation, namely the randomized controlled trial. The actual benefit observed divided by the potential benefit gives fraction of benefit (FOB). This varies from almost 100% for stroke to 60% for coronary heart disease.
(d) By how much does bloodpressure have to be reduced to achieve the benefit?
This question is very complex as it is probable that the benefits are related both to the untreated pressure and to the pressure achieved by treatment (the reduction in pressure is simply the mathematical difference between the pressures). Moreover, there may or may not be a linear relationship between morbidity and achieved pressure. The possibility that blood pressure can be reduced too far has to be addressed in view of the debate over the J-shaped curve in which cardiac mortality 'increases' somewhat at the lowest levels of diastolic blood pressure.
Providing answers to these four questions is so difficult that the only solution is to The trial results will be discussed for the three groups where it is available and the other groups are reviewed subsequently.
Persons aged 40-59, diastolic hypertension ± systolic hypertension Benefits-stroke reduction Collins and his colleagues3 have performed a meta-analysis of the trial data and concluded that anti-hypertensive treatment reduces stroke events by an average of 42% (range 33-50% for the trials). They concluded that epidemiological data would suggest a reduction of 35-40% for the equivalent reduction in blood pressure and therefore the FOB obtained was 100%. Their analysis includes some ofthe trials in the elderly but the treatment effect was similar in proportional terms for age range 40-59 and 60-79. Collins et al. also included the Hypertension Detection and Follow-up Program (HDFP) trial4 which included not only more effective treatment of hypertension but also other health care measures that reduced non-cardiovascular deaths. However, the results of this trial tended to reduce the size of the effect on stroke (at least in women) and not to increase it. The consistency of the trial data has led many authorities to assume that it is the blood pressure lowering effect of anti-hypertensive drugs that confers the reduction in stroke incidence and that all drugs should be equally efficacious ifthey reduce pressure by a given amount. Nevertheless, stroke In the HDFP trial, there was some evidence for a reduction in coronary events in women. In this trial, however, although white women had only a 4 mmHg reduction in DBP in the stepped (intensive) care group compared to the usual care group, stroke was reduced by 29%9 and myocardial infarction (for all women -black and white) by 14%.' The latter effect led to a high reduction in risk but the diagnosis of a non-fatal MI also depended on responses to a questionnaire, the Rose Questionnaire" and ischaemic cardiac pain reported in this way may have less clinical significance in terms of mortality than a formal diagnosis of MI.'2 The incidence rates would be reduced by about a half if questionnaire-positive cases were omitted from the HDFP results'0 giving a lower reduction in risk of 0.3 per 1,000 patient years.
The MRC and HDFP data for white women suggest that total mortality is not reduced by the treatment of mild hypertension over a 5 year period.
These data on younger persons do not fit exactly into the age category 40-59, as the age range in this Australian and HDFP trials extended to 69 years, and to 65 years in the MRC trial. However, the benefits appear to apply to the age range 40-59 years as much as for age 60-69. All entries are significant at the I % level and represent the difference between the rate on active treatment and the rate on placebo. A zero entry means no statistically significant excess or deficit. 26 The Hypertension in the Elderly Persons (HEP) trial27 was based on atenolol and the STOP hypertension trial28 was based on either a diuretic or one of several beta-blockers. In the event the vast majority of patients in this trial ended up on a diuretic. The MRC trial in the elderly29 randomized active treatment to be based either on the betablocker atenolol or to a hydrochlorothiazide/ amiloride diuretic combination. Five of the trials were concerned predominantly with diastolic hypertension but the SHEP trial was concerned exclusively with isolated systolic hypertension and will be considered in a later section. Table VII gives the results in the MRC trial according to the randomized treatment. Both the diuretic and the beta-blocker lowered stroke rates with a tendency for a lower rate on the diuretic in non-smokers.
Benefits -reduction in cardiac events
In the MRC elderly trial total coronary events were reduced by 44% with a hydrochlorothiazide/amiloride combination but not by atenolol29 (Table VII) . In other studies employing a beta-blocker (Table  VI) the reductions in total cardiac events were 15% (the HEP trial27), and 13% (the STOP trial28). The corresponding reductions when a diuretic was employed were 19% (Australian trial, age 60-6924), and 20% (EWPHE trial25). In the MRC elderly trial29 the investigators have reported benefits from using a diuretic over and above the effects of lowering blood pressure and a similar finding has been reported in the STOP trial for all active treatment.28 30 Any benefits from treatment with a beta-blocker were confined to non-smokers. In view of these findings, Beard et al.3" recommended diuretics rather than beta-blockers for elderly patients with uncomplicated hypertension. As the earlier MRC trial indicated a doubt concerning the ability of propranolol to reduce stroke events or coronary events in smokers this may be good advice. Although the benefits of beta-blockers are fully established in the secondary prevention ofMI, the possibility that this action could be translated into a beneficial effect on primary prevention could only be observed in young non-smokers. It would appear wise to avoid beta-blockers in the elderly and this would appear reasonable if we take into account the greater tendency of the elderly to heart failure and chronic obstructive airways disease. In the elderly and the middle-aged male smoker, diuretic treatment may be preferable as first line treatment. Table VII indicates that total mortality was not reduced in the atenolol group of the MRC elderly trial. The cardiovascular event rate is much higher in the elderly and these persons have more to gain from treatment. Table VIII gives the number of patients that need to be treated for 5 years to prevent one event. The returns from treating the elderly are much greater than for younger persons. In the more hypertensive patients in the EWPHE trial (average untreated pressure 182/101 mmHg) only 1(0 have to be treated for 5 years to prevent both a stroke event and a cardiac event.
The risks
In the trials the risks of treatment depend on the exact nature of the anti-hypertensive treatment and range from potentially life-threatening events, to biochemical changes not known to be associated with symptoms, and to adverse effects on quality of life. The risks in the EWPHE and MRC elderly trials are given in Table IX. In the EWPHE trial important consequences of diuretic treatment included gout, 4/1,000/year and diabetes mellitus 9/1,000/year.25 The latter was associated with starting oral hypoglycaemic drugs in 7/1,000/year. Active treatment was also associated with a need for peripheral vasodilators in 7/1,000/year.32 Table IX also indicates that a certain degree of mild hypokalaemia and an elevated serum creatinine will be expected in actively treated patients. As deaths from cardiac causes and renal failure were not increased on active treatment these biochemical changes were presumably, on balance, of little clinical importance. An excess of 12% of patients reported dry mouth and 7% diarrhoea. These symptoms appeared to be mainly due to the methyldopa treatment received by a third of patients on active treatment.
These risks must be contrasted with the benefits. For example, in the EWPHE trial 4/1,000 will get gout in 1 year, nine diabetes and over 120/1,000 will get side effects of drugs. Set against this is the saving ofsix per 1,000 for fatal strokes, 11/1,000 for non-fatal strokes, 11 / 1,000 for fatal cardiac events and 8/1,000 for episodes of severe congestive heart failure.
In the MRC trial the adverse events leading to withdrawal have been published and are given in Table IX . The burden of adverse events appear similar to that in the EWPHE trial. The side effects only appear to be less frequent as these adverse events had to be severe enough to cause withdrawal of the patient from the treatment.
These risks have to be compared with the gains in all treated patients of 3/1,000 patient years for all strokes, and 2/1,000 for all coronary events. For diuretic treatment the gains were 4/ 1,000 and 5/1,000 patient years, respectively. 
Conclusions
The risk-benefit analysis in the EWPHE trial is clearly in favour of treatment. In the MRC elderly trial, the results are less convincing but do support a policy of treating the patients entered in the EWPHE trial -those with sustained DBP > 90 mmHg plus SBP > 160 mmHg.
Persons aged 60-79, isolated systolic hypertension
Only one large trial has investigated the effect of treating isolated systolic hypertension, the Systolic Hypertension in the Elderly Program (SHEP) trial.26 This trial only included persons over the age of 60, average age 72 years. Table X gives the benefits observed in this trial. Fatal cerebrovascular events were little influenced by treatment but non-fatal strokes were reduced by 5/1,000 patient years. Fatal coronary events were reduced by 2/1,000 patient years, non-fatal myocardial infarction also by 2/1,000/year, left ventricular failure by 5/1,000/year and coronary artery bypass grafting by 2/1,000/year. Forty-three per cent of the MRC elderly trial had isolated systolic hypertension and the trial reported 'there is no reason to doubt the applicability of the overall trial results to those with isolated systolic hypertension'.
The risks for treatment in the SHEP trial are also given in Table X . The biochemical adverse effects appear to be qualitatively and quantitatively similar to those observed in the other trials. In view of the fact that cardiac morbidity and mortality were reduced by active treatment, the increases in serum glucose and cholesterol and reductions in serum potassium did not produce a net increase in adverse cardiac events. However, from the patient's point of view the increases in serum uric acid and glucose are likely to have had clinical consequences in some patients, namely those who developed gout or symptoms due to diabetes mellitus.
The SHEP research group reported on 29 symptoms, 27 of which were more frequent in the actively treated group. The exceptions were 'heart beating fast or skipping beats' and 'severe headaches'. The nine symptoms with the greatest excess in the actively treated group are given in Table X . In a separate publication the trial has reported that active treatment increased the time to complete the Reitan Trail Making Test by 3 seconds.33 This test of psychomotor speed and cognition is compatible with the report of an excess of memory problems in 60/1,000 in Table X . The excess of chest pain and pain in joints is surprising but the complaint ofcold hands and swollen ankles may be related to the use of atenolol or other betaadrenoceptor drugs that were employed in over 20% of actively treated patients.
The risks from treating isolated systolic hypertension appear to be as great as for treating combined systolic and diastolic hypertension, yet the absolute benefits are less, at least for mortal events. In proportional terms the evidence so far 
